Xu Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xu Liang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Huiping Li
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
3 shared publications Lijun Di
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute , Beijing 100142
3 shared publicationsXinyu Gui
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute , Beijing 100142
3 shared publications- Guohong Song
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
2 shared publications Ying Yan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute , Beijing 100142
2 shared publicationsBin Shao
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute , Beijing 100142
1 shared publication
Latest Publications
- 22 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (2) , 123-131
Al18F-NOTA-HER2-BCH Versus 18F-FDG PET/CT for Detecting Bone Metastases
Purpose: To compare the performance of Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT in detecting bone metastases, with or without visceral metastases, in HER2-positive breast cancer patients. Methods: This retrospective study included 64 participants with HER2-positive breast cancer who underwent both Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT. All participants had pathologically confirmed HER2-positive status, defined as either IHC 3+ or IHC 2+ with gene amplification on FISH. Two independent readers visually assessed uptake of tracers on imaging. Bone lesions were classified as osteolytic, osteoblastic, mixed-pattern, or CT-occult based on their radiographic characteristics. Lesion uptake was quantified using both maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), with statistical comparison performed through general linear mixed modeling. Final diagnoses were established through histopathologic confirmation or clinical follow-up. Results: The findings showed bone metastases in 23 (35.9%) participants, including 2 (8.7%) had pure bone metastases, 21 (91.3%) concurrent visceral metastases. On a per-patient analysis, the sensitivity, specificity, and accuracy of Al 18 F-NOTA-HER2-BCH and 18 F-FDG were 100.0%, 95.1%, 96.9%, and 87.0%, 97.6%, 93.8%, respectively. Three (13.0%) participants were visualized only on Al 18 F-NOTA-HER2-BCH, and 10 (43.5%) were detected more lesions on Al 18 F-NOTA-HER2-BCH than 18 F-FDG PET/CT. Regarding visceral metastases, Al 18 F-NOTA-HER2-BCH alone detected metastases in 4 participants (19.0%), identified more lesions than 18 F-FDG in 5 participants (23.8%), and showed equal detection in 12 participants (57.1%). On a per-lesion analysis, PET/CT identified 238 bone metastases, with Al 18 F-NOTA-HER2-BCH achieving complete detection (238/238, 100%) compared with 18 F-FDG’s identification of only 143 lesions (143/238, 60.1%). Notable detection differences emerged in: osteoblastic (100% vs. 0%), osteolytic (100% vs. 87.5%), and CT-occult lesions (100% vs. 50.6%) for Al 18 F-NOTA-HER2-BCH versus 18 F-FDG, respectively. Quantitative comparison revealed Al 18 F-NOTA-HER2-BCH PET/CT achieved 2.7–5.9 folds higher SUVmax and TBR values versus 18 F-FDG PET/CT across osteogenic, osteolytic, and CT-occult lesions ( P 18 F-NOTA-HER2-BCH detected more bone metastases small than 10 mm than 18 F-FDG PET/CT (183 vs. 95, 100.0% vs. 50.3%). No adverse reactions related to imaging agents were observed in all participants. Conclusions: Compared with 18 F-FDG PET/CT, Al 18 F-NOTA-HER2-BCH PET/CT demonstrated superior detection of bone metastases in HER2-positive breast cancer participants, particularly for early-stage CT-occult lesions and sub-centimeter (<10 mm) metastases. In addition, it showed potential for earlier identification of concurrent visceral metastases.
- 22 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (2) , 123-131
Al18F-NOTA-HER2-BCH Versus 18F-FDG PET/CT for Detecting Bone Metastases
Purpose: To compare the performance of Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT in detecting bone metastases, with or without visceral metastases, in HER2-positive breast cancer patients. Methods: This retrospective study included 64 participants with HER2-positive breast cancer who underwent both Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT. All participants had pathologically confirmed HER2-positive status, defined as either IHC 3+ or IHC 2+ with gene amplification on FISH. Two independent readers visually assessed uptake of tracers on imaging. Bone lesions were classified as osteolytic, osteoblastic, mixed-pattern, or CT-occult based on their radiographic characteristics. Lesion uptake was quantified using both maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), with statistical comparison performed through general linear mixed modeling. Final diagnoses were established through histopathologic confirmation or clinical follow-up. Results: The findings showed bone metastases in 23 (35.9%) participants, including 2 (8.7%) had pure bone metastases, 21 (91.3%) concurrent visceral metastases. On a per-patient analysis, the sensitivity, specificity, and accuracy of Al 18 F-NOTA-HER2-BCH and 18 F-FDG were 100.0%, 95.1%, 96.9%, and 87.0%, 97.6%, 93.8%, respectively. Three (13.0%) participants were visualized only on Al 18 F-NOTA-HER2-BCH, and 10 (43.5%) were detected more lesions on Al 18 F-NOTA-HER2-BCH than 18 F-FDG PET/CT. Regarding visceral metastases, Al 18 F-NOTA-HER2-BCH alone detected metastases in 4 participants (19.0%), identified more lesions than 18 F-FDG in 5 participants (23.8%), and showed equal detection in 12 participants (57.1%). On a per-lesion analysis, PET/CT identified 238 bone metastases, with Al 18 F-NOTA-HER2-BCH achieving complete detection (238/238, 100%) compared with 18 F-FDG’s identification of only 143 lesions (143/238, 60.1%). Notable detection differences emerged in: osteoblastic (100% vs. 0%), osteolytic (100% vs. 87.5%), and CT-occult lesions (100% vs. 50.6%) for Al 18 F-NOTA-HER2-BCH versus 18 F-FDG, respectively. Quantitative comparison revealed Al 18 F-NOTA-HER2-BCH PET/CT achieved 2.7–5.9 folds higher SUVmax and TBR values versus 18 F-FDG PET/CT across osteogenic, osteolytic, and CT-occult lesions ( P 18 F-NOTA-HER2-BCH detected more bone metastases small than 10 mm than 18 F-FDG PET/CT (183 vs. 95, 100.0% vs. 50.3%). No adverse reactions related to imaging agents were observed in all participants. Conclusions: Compared with 18 F-FDG PET/CT, Al 18 F-NOTA-HER2-BCH PET/CT demonstrated superior detection of bone metastases in HER2-positive breast cancer participants, particularly for early-stage CT-occult lesions and sub-centimeter (<10 mm) metastases. In addition, it showed potential for earlier identification of concurrent visceral metastases.
- Open Access
- 4 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (7)
Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer
Background: HLX02 (Zercepac®) is the first trastuzumab biosimilar manufactured in China. This study presents the first real-world comparison of HLX02 with reference trastuzumab (RTZ) plus pertuzumab and chemotherapy as the first-line treatment for HER2-positive metastatic breast cancer (MBC) patients. Methods: Medical data of patients with HER2-positive MBC who received HLX02 or RTZ, both combined with pertuzumab and various chemotherapies as the first-line therapy at Beijing Cancer Hospital from January 2019 to August 2023 were reviewed retrospectively. The survival outcomes, efficacy, and adverse events were analyzed. Results: In total, 118 patients were included in this study retrospectively, among whom 66 patients received RTZ and 52 received HLX02. No significant difference was observed in progression-free survival (PFS) between the groups (median PFS: 22.0 months for RTZ vs. 19.0 months for HLX02, P = .832). Additionally, the objective response rate, disease control rate, and safety profiles were similar across both groups. Of all 118 patients, 20 (16.9%) patients experienced progression in the central nervous system (CNS), with a median time to CNS progression of 15.0 months (95% confidence interval, CI, 12.8–17.2). Conclusion: The real-world data suggested that both HLX02 and RTZ, when combined with pertuzumab and various chemotherapy regimens, offer comparable efficacy and safety as first-line treatments for HER2-positive advanced breast cancer patients in China.
- 4 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (7)
Open AccessReal-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer
Background: HLX02 (Zercepac®) is the first trastuzumab biosimilar manufactured in China. This study presents the first real-world comparison of HLX02 with reference trastuzumab (RTZ) plus pertuzumab and chemotherapy as the first-line treatment for HER2-positive metastatic breast cancer (MBC) patients. Methods: Medical data of patients with HER2-positive MBC who received HLX02 or RTZ, both combined with pertuzumab and various chemotherapies as the first-line therapy at Beijing Cancer Hospital from January 2019 to August 2023 were reviewed retrospectively. The survival outcomes, efficacy, and adverse events were analyzed. Results: In total, 118 patients were included in this study retrospectively, among whom 66 patients received RTZ and 52 received HLX02. No significant difference was observed in progression-free survival (PFS) between the groups (median PFS: 22.0 months for RTZ vs. 19.0 months for HLX02, P = .832). Additionally, the objective response rate, disease control rate, and safety profiles were similar across both groups. Of all 118 patients, 20 (16.9%) patients experienced progression in the central nervous system (CNS), with a median time to CNS progression of 15.0 months (95% confidence interval, CI, 12.8–17.2). Conclusion: The real-world data suggested that both HLX02 and RTZ, when combined with pertuzumab and various chemotherapy regimens, offer comparable efficacy and safety as first-line treatments for HER2-positive advanced breast cancer patients in China.
- Open Access
- 4 June 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (6)
Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors
Background: Preclinical models demonstrated promising anti-tumor activity of SPH4336, a novel oral, highly selective cyclin-dependent kinase (CDK) 4/6 inhibitor. Methods: This phase I study enrolled patients who received SPH4336 orally in 6 dose-escalation cohorts (50-600 mg) in a 3 + 3 design. Based on tolerability, pharmacokinetics (PK) and activity data from the dose-escalation phase, 2-3 dose cohorts were expanded. Dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), efficacy, safety, tolerability, and pharmacokinetics (PK) were investigated. Results: A total of 29 patients with breast cancer (BC) (n = 14), sarcoma (n = 8), non-small cell lung cancer (n = 2) and others (n = 5) were enrolled. Neither DLT nor MTD were reached. All patients had at least one treatment-related adverse events (TRAEs), most of which were grade 1/2. Grade ≥ 3 TRAEs occurred in 51.7% of patients. One patient died from disease progression and five reported serious adverse events. Plasma concentrations increased dose-dependently, except at 600 mg, and steady state was reached at 2 weeks for 400 mg. One BC patient in the 600-mg cohort had a confirmed partial response. The disease control rate was 59.3% (95% CI, 38.8-77.6). Conclusion: SPH4336 demonstrated an acceptable safety profile and dose-dependent plasma exposure in patients with various advanced solid tumors. (ClinicalTrials.gov Identifier: NCT05905614; IRB Approved.)
- 4 June 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (6)
Open AccessPhase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors
Background: Preclinical models demonstrated promising anti-tumor activity of SPH4336, a novel oral, highly selective cyclin-dependent kinase (CDK) 4/6 inhibitor. Methods: This phase I study enrolled patients who received SPH4336 orally in 6 dose-escalation cohorts (50-600 mg) in a 3 + 3 design. Based on tolerability, pharmacokinetics (PK) and activity data from the dose-escalation phase, 2-3 dose cohorts were expanded. Dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), efficacy, safety, tolerability, and pharmacokinetics (PK) were investigated. Results: A total of 29 patients with breast cancer (BC) (n = 14), sarcoma (n = 8), non-small cell lung cancer (n = 2) and others (n = 5) were enrolled. Neither DLT nor MTD were reached. All patients had at least one treatment-related adverse events (TRAEs), most of which were grade 1/2. Grade ≥ 3 TRAEs occurred in 51.7% of patients. One patient died from disease progression and five reported serious adverse events. Plasma concentrations increased dose-dependently, except at 600 mg, and steady state was reached at 2 weeks for 400 mg. One BC patient in the 600-mg cohort had a confirmed partial response. The disease control rate was 59.3% (95% CI, 38.8-77.6). Conclusion: SPH4336 demonstrated an acceptable safety profile and dose-dependent plasma exposure in patients with various advanced solid tumors. (ClinicalTrials.gov Identifier: NCT05905614; IRB Approved.)
- Open Access
Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
Background: Cyclin‐dependent kinase 4/6 inhibitors combined with endocrine therapy (ET) comprise the standard treatment for patients with hormone receptor‐positive and human epidermal growth factor 2 (HER2)‐negative metastatic breast cancer. The optimal systematic treatment after progression on palbociclib and the role of HER2 expression among these patients remain unclear.Methods: The authors retrospectively identified 361 patients who received palbociclib combined with ET. Progression‐free survival (PFS) and overall survival (OS) were analyzed based on subsequent treatments and HER2 status (PFSsub and OSsub, respectively). PFS1 and OS1 were calculated from palbociclib administration to disease progression/death and death from any cause, respectively. PFSsub and OSsub were calculated from subsequent treatment initiation.Results: The median PFS1 and OS1 were 10.2 and 39.9 months, respectively. The median PFSsub and OSsub of 111 patients (54.7%) who received chemotherapy were 4.9 months and 20.0 months, respectively, whereas those of 89 patients (43.8%) who received endocrine backbone therapy were 5.9 months and 29.3 months, respectively. Among them, 31 patients (15.3%) who received abemaciclib combined with new ET showed better PFSsub and OSsub (12.2 months and not reached, respectively). The median PFS1 was significantly shorter in the HER2‐low subgroup than in the HER2‐zero subgroup among patients who received second‐line or later palbociclib (6.1 vs. 7.8 months; p = .040) but did not differ among patients who received first‐line palbociclib.Conclusions: Various regimens after palbociclib use were received. An improvement was noted in PFS among patients who received endocrine backbone therapy relative to chemotherapy, which may have been secondary to the receipt of chemotherapy by patients with more aggressive disease. HER2 status was not related to the effect of first‐line palbociclib, but it may play a role in later lines.
Open AccessReal‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
Background: Cyclin‐dependent kinase 4/6 inhibitors combined with endocrine therapy (ET) comprise the standard treatment for patients with hormone receptor‐positive and human epidermal growth factor 2 (HER2)‐negative metastatic breast cancer. The optimal systematic treatment after progression on palbociclib and the role of HER2 expression among these patients remain unclear.Methods: The authors retrospectively identified 361 patients who received palbociclib combined with ET. Progression‐free survival (PFS) and overall survival (OS) were analyzed based on subsequent treatments and HER2 status (PFSsub and OSsub, respectively). PFS1 and OS1 were calculated from palbociclib administration to disease progression/death and death from any cause, respectively. PFSsub and OSsub were calculated from subsequent treatment initiation.Results: The median PFS1 and OS1 were 10.2 and 39.9 months, respectively. The median PFSsub and OSsub of 111 patients (54.7%) who received chemotherapy were 4.9 months and 20.0 months, respectively, whereas those of 89 patients (43.8%) who received endocrine backbone therapy were 5.9 months and 29.3 months, respectively. Among them, 31 patients (15.3%) who received abemaciclib combined with new ET showed better PFSsub and OSsub (12.2 months and not reached, respectively). The median PFS1 was significantly shorter in the HER2‐low subgroup than in the HER2‐zero subgroup among patients who received second‐line or later palbociclib (6.1 vs. 7.8 months; p = .040) but did not differ among patients who received first‐line palbociclib.Conclusions: Various regimens after palbociclib use were received. An improvement was noted in PFS among patients who received endocrine backbone therapy relative to chemotherapy, which may have been secondary to the receipt of chemotherapy by patients with more aggressive disease. HER2 status was not related to the effect of first‐line palbociclib, but it may play a role in later lines.
- Open Access
- 17 August 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (2) , e198-e205
Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study
Pyrotinib is currently approved for the treatment of HER2-positive advanced breast cancer in China. Data on the overall survival (OS) and efficacy in patients with brain metastasis (BM) remain scarce. This study evaluated the effectiveness of pyrotinib in a real-world setting, especially in patients with BM. We reviewed patients with metastatic breast cancer treated with pyrotinib-based therapy between June 2018 and June 2022. Progression-free survival (PFS), OS, objective response rate, and safety were analyzed following the administration of pyrotinib. A total of 239 patients were included. The median PFS in patients who received pyrotinib-based therapy as first-line (15/239), second-line (115/239), or third-or-higher-line (109/239) treatment was 14.00, 9.33, and 8.20 months, respectively, and the median OS was not reached, 29.07 and 22.23 months, respectively. The median PFS in patients who pretreated with trastuzumab (214/239), trastuzumab plus pertuzumab (22/239), lapatinib (68/239), or trastuzumab emtansine (14/239) was 9.33, 6.87, 7.20, and 7.20 months, respectively. In 61 patients with BM, the median PFS was 7.50 months, the median central nervous system (CNS)-PFS was 11.17 months, and the median OS was 21.27 months. Furthermore, 19 patients with concomitant brain radiotherapy tended to achieve a longer OS than 42 patients without radiation (34.17 vs. 20.70 months, P = .112). Long-term outcomes of pyrotinib-based therapy are promising for patients with HER2-positive metastatic breast cancer in real world and in patients with BM, regardless of the treatment lines and prior anti-HER2 therapies.
- 17 August 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (2) , e198-e205
Open AccessLong-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study
Pyrotinib is currently approved for the treatment of HER2-positive advanced breast cancer in China. Data on the overall survival (OS) and efficacy in patients with brain metastasis (BM) remain scarce. This study evaluated the effectiveness of pyrotinib in a real-world setting, especially in patients with BM. We reviewed patients with metastatic breast cancer treated with pyrotinib-based therapy between June 2018 and June 2022. Progression-free survival (PFS), OS, objective response rate, and safety were analyzed following the administration of pyrotinib. A total of 239 patients were included. The median PFS in patients who received pyrotinib-based therapy as first-line (15/239), second-line (115/239), or third-or-higher-line (109/239) treatment was 14.00, 9.33, and 8.20 months, respectively, and the median OS was not reached, 29.07 and 22.23 months, respectively. The median PFS in patients who pretreated with trastuzumab (214/239), trastuzumab plus pertuzumab (22/239), lapatinib (68/239), or trastuzumab emtansine (14/239) was 9.33, 6.87, 7.20, and 7.20 months, respectively. In 61 patients with BM, the median PFS was 7.50 months, the median central nervous system (CNS)-PFS was 11.17 months, and the median OS was 21.27 months. Furthermore, 19 patients with concomitant brain radiotherapy tended to achieve a longer OS than 42 patients without radiation (34.17 vs. 20.70 months, P = .112). Long-term outcomes of pyrotinib-based therapy are promising for patients with HER2-positive metastatic breast cancer in real world and in patients with BM, regardless of the treatment lines and prior anti-HER2 therapies.
- Open Access
- 5 July 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (16) , 16793-16804
Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
Introduction: Eribulin is currently recommended for the treatment of patients with metastatic breast cancer (MBC) pre‐treated with taxanes and anthracyclines. The aim of the present study was to evaluate the effectiveness and safety of eribulin and its impact on health‐related quality of life in heavily pre‐treated patients with MBC.Methods: Data from MBC patients who had received eribulin‐based therapy at Beijing Cancer Hospital between January 2020 and July 2022 were analyzed retrospectively. Progression‐free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse effects (AEs) and health‐related quality of life (HRQoL) were assessed.Results: Data from 118 patients who had received eribulin to treat MBC were included. Median PFS was 4.2 months and median OS had not been reached. The ORR was 13.6% (16/118) and DCR was 75.4% (89/118). The median PFS in patients who received eribulin in second‐line (26/118), third‐line (29/118), or fourth‐line or later (63/118) was 4.5, 4.2, and 3.9 months, respectively. The median OS in patients who received eribulin in third‐ or later line (n = 92) was 14.1 months. Patients who received eribulin combination therapy had a significantly longer median PFS compared with those who received eribulin monotherapy (4.5 vs. 3.4 months, p = 0.007) and there was a trend towards a longer median OS (not reached vs. 12.1 months). The most common grade 3–4 adverse events were neutropenia (22.9%), leukocytopenia (13.6%) and asthenia/fatigue (8.5%), without significant differences in safety between eribulin monotherapy and combination therapy. Quality of life was similar in patients who received eribulin monotherapy and combination therapy, except for cognitive function and nausea and vomiting symptoms, which were better with combination therapy.Conclusions: The present study suggests that eribulin‐based therapy is an effective treatment option and well tolerated for heavily pre‐treated patients with MBC. Eribulin combination therapy might improve PFS and HRQoL compared with eribulin monotherapy.
- 5 July 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (16) , 16793-16804
Open AccessEffectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
Introduction: Eribulin is currently recommended for the treatment of patients with metastatic breast cancer (MBC) pre‐treated with taxanes and anthracyclines. The aim of the present study was to evaluate the effectiveness and safety of eribulin and its impact on health‐related quality of life in heavily pre‐treated patients with MBC.Methods: Data from MBC patients who had received eribulin‐based therapy at Beijing Cancer Hospital between January 2020 and July 2022 were analyzed retrospectively. Progression‐free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse effects (AEs) and health‐related quality of life (HRQoL) were assessed.Results: Data from 118 patients who had received eribulin to treat MBC were included. Median PFS was 4.2 months and median OS had not been reached. The ORR was 13.6% (16/118) and DCR was 75.4% (89/118). The median PFS in patients who received eribulin in second‐line (26/118), third‐line (29/118), or fourth‐line or later (63/118) was 4.5, 4.2, and 3.9 months, respectively. The median OS in patients who received eribulin in third‐ or later line (n = 92) was 14.1 months. Patients who received eribulin combination therapy had a significantly longer median PFS compared with those who received eribulin monotherapy (4.5 vs. 3.4 months, p = 0.007) and there was a trend towards a longer median OS (not reached vs. 12.1 months). The most common grade 3–4 adverse events were neutropenia (22.9%), leukocytopenia (13.6%) and asthenia/fatigue (8.5%), without significant differences in safety between eribulin monotherapy and combination therapy. Quality of life was similar in patients who received eribulin monotherapy and combination therapy, except for cognitive function and nausea and vomiting symptoms, which were better with combination therapy.Conclusions: The present study suggests that eribulin‐based therapy is an effective treatment option and well tolerated for heavily pre‐treated patients with MBC. Eribulin combination therapy might improve PFS and HRQoL compared with eribulin monotherapy.